R. Nowack et al., EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ON RENAL SODIUM HANDLING AFTER FUROSEMIDE INJECTION, The Clinical investigator, 71(8), 1993, pp. 622-627
The goal of this study was to quantitate the effect of angiotensin-con
verting enzyme inhibition on renal sodium handling after furosemide in
jection. The study was carried out on low and normal salt intake to as
sess potential interaction with salt balance. Eighteen healthy normote
nsive volunteers were examined in a double placebo-controlled parallel
group design. Subjects were randomly put on either low-salt (20 mmol/
day) or normal-salt (110 mmol/day) diet. In either arm of the diet vol
unteers were first treated orally with placebo for 1 week and subseque
ntly with 2.5 mg/day of the angiotensin-converting enzyme inhibitor ci
lazapril for another 1 week. Cumulative 24-h urinary sodium excretion
was measured on the 6th day of the respective week after sham injectio
n and on the 7th day after injection of 40 mg furosemide. Compared to
pretreatment with placebo, pretreatment with cilazapril resulted in a
higher cumulative sodium excretion after furosemide injection (day 7)
than after the sham injection (day 6) on both salt intakes. The differ
ence in natriuresis (cilazapril versus placebo) was evident 2 and 3 h
after injection of furosemide. Neither the time of onset nor the magni
tude of antinatriuresis were affected by cilazapril. Following furosem
ide angiotensin II increased significantly even after cilazapril pretr
eatment. Cilazapril tended to reduce urinary furosemide excretion. At
any given urinary furosemide concentration, the increment in urinary s
odium excretion was significantly greater with cilazapril irrespective
of salt intake. The study shows that (a) cilazapril increases furosem
ide-induced natriuresis irrespective of salt intake, (b) antinatriures
is is not affected by cilazapril, and (c) angiotensin II levels rise a
fter furosemide on cilazapril in therapeutic doses.